Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 12Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 11Colorectal Neoplasms 9Triple Negative Breast Neoplasms 8Neoplasms 6Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Renal Cell 5Stomach Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Glioblastoma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lung Neoplasms 2Liver Neoplasms 2Hematologic Diseases 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Advanced Solid Tumors 2Advanced Solid Tumor 2Adenocarcinoma 2von Hippel-Lindau Disease 1

Interventions

Azacitidine 23fludarabine phosphate 17Cyclophosphamide 16Decitabine 12Cytarabine 11Peripheral Blood Stem Cell Transplantation 10Whole-Body Irradiation 9Mycophenolic Acid 9Filgrastim 8Tacrolimus 7Cyclosporine 7venetoclax 6decitabine and cedazuridine drug combination 6fludarabine 5Carboplatin 5sargramostim 4Vorinostat 4Specimen Handling 4Sirolimus 4Radiotherapy 4Injections 4Cyclosporins 4Clofarabine 4Busulfan 4ruxolitinib 3cedazuridine 3aldesleukin 3Topotecan 3Melphalan 3Leucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelomonocytic, Chronic × spartalizumab × Clear all
NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Novartis

Phase 1 Completed
241 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡